PON-P: Integrated predictor for pathogenicity of missense variants

Human Mutation

Volumn 33, Issue 8, 2012, Pages 1166-1174

  Olatubosun, Ayodeji ^a,b   Väliaho, Jouni ^a,b   Härkönen, Jani ^a   Thusberg, Janita ^a   Vihinen, Mauno ^a,b,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Classification with reject option; Consensus prediction; Methods integration; Variation tolerance prediction

Indexed keywords

ADULT; ARTICLE; CANCER CELL CULTURE; CONSENSUS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MISSENSE MUTATION; PATHOGENESIS; PATHOGENIC OR NOT PIPELINE; PATHOGENICITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROTEIN FUNCTION; RANDOM FOREST; RELIABILITY; VALIDATION PROCESS;

COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION, MISSENSE;

HARNESS;

EID: 84863875423     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22102     Document Type: Article

References (66)

1. 1000 Genomes Project Consortium. 2010. A map of human genome variation from population-scale sequencing. Nature 467:1061-1073.
2. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. Nat Methods 7:248-249.
3. Ali H, Olatubosun A, Vihinen M. 2012. Classification of mismatch repair gene missense variants with PON-MMR. Hum Mutat 33:642-650.
4. Ayala I, Giacchetti G, Caldieri G, Attanasio F, Mariggio S, Tete S, Polishchuk R, Castronovo V, Buccione R. 2009. Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer. Cancer Res 69:747-752.
5. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H. 2000. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 16:412-424.
6. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ. 2005. Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol Carcinog 44:151-161.
7. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS. 2007. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 26:683-700.
8. Binkley J, Karra K, Kirby A, Hosobuchi M, Stone EA, Sidow A. 2010. ProPhylER: a curated online resource for protein function and structure based on evolutionary constraint analyses. Genome Res 20:142-154.
9. Breiman L. 2001. Random forests. Mach Learn 45:5-32.
10. Breiman L, Friedman J, Ohlsen R, Stone C. 1984. Classification and regression trees. Wadsworth, Belmont, CA: Chapman and Hall/CRC.
11. Bromberg Y, Rost B. 2007. SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res 35:3823-3835.
12. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. 2009. Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat 30:1237-1244.
13. Capriotti E, Calabrese R, Casadio R. 2006. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics 22:2729-2734.
14. Capriotti E, Fariselli P, Rossi I, Casadio R. 2008. A three-state prediction of single point mutations on protein stability changes. BMC Bioinformatics 9 Suppl 2:S6.
15. Chow C. 1970. On optimum recognition error and reject tradeoff. IEEE Trans Inf Theory 16:41-46.
16. Clifford RJ, Edmonson MN, Nguyen C, Buetow KH. 2004. Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms. Bioinformatics 20:1006-1014.
17. Cline MS, Karchin R. 2011. Using bioinformatics to predict the functional impact of SNVs. Bioinformatics 27:441-448.
18. Dubuisson B, Masson M. 1993. A statistical decision rule with incomplete knowledge about classes. Pattern Recogn 26:155-165.
19. Fawcett T. 2006. An introduction to ROC analysis. Pattern Recogn Lett 27:861-874.
20. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. 2003. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63:4626-4631.
21. Fernald GH, Capriotti E, Daneshjou R, Karczewski KJ, Altman RB. 2011. Bioinformatics challenges for personalized medicine. Bioinformatics 27:1741-1748.
22. Firlej V, Ladam F, Brysbaert G, Dumont P, Fuks F, de Launoit Y, Benecke A, Chotteau-Lelievre A. 2008. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or erm-dependent transcription. J Cell Sci 121:3393-3402.
23. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Chen Y, Clapham P, Coates G, Fairley S, Fitzgerald S, Gordon L, Hendrix M, et al. 2011. Ensembl 2011. Nucleic Acids Res 39:D800-D806.
24. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA. 2011. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945-D950.
25. Giardine B, Riemer C, Hefferon T, Thomas D, Hsu F, Zielenski J, Sang Y, Elnitski L, Cutting G, Trumbower H, Kern A, Kuhn R, et al. 2007. PhenCode: connecting ENCODE data with mutations and phenotype. Hum Mutat 28:554-562.
26. González-Pérez A, López-Bigas N. 2011. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, condel. Am J Hum Genet 88:440-449.
27. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
28. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA. 2007. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67:4219-4226.
29. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS. 2005. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 65:11572-11580.
30. Hsu T, Trojanowska M, Watson DK. 2004. Ets proteins in biological control and cancer. J Cell Biochem 91:896-903.
31. Jain E, Bairoch A, Duvaud S, Phan I, Redaschi N, Suzek BE, Martin MJ, McGarvey P, Gasteiger E. 2009. Infrastructure for the life sciences: design and implementation of the UniProt website. BMC Bioinformatics 10:136.
32. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
33. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, et al. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869-873.
34. Kawabata T, Ota M, Nishikawa K. 1999. The protein mutant database. Nucleic Acids Res 27:355-357.
35. Khan S, Vihinen M. 2010. Performance of protein stability predictors. Hum Mutat 31:675-684.
36. Kido K, Sumimoto H, Asada S, Okada SM, Yaguchi T, Kawamura N, Miyagishi M, Saida T, Kawakami Y. 2009. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation. Cancer Sci 100:1863-1869.
37. Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073-1081.
38. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. 2007. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96:1083-1091.
39. Kurada BR, Li LC, Mulherkar N, Subramanian M, Prasad KV, Prabhakar BS. 2009. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. J Biol Chem 284:13533-13541.
40. Landgrebe T, Tax J, Paclk P, Duin W. 2006. The interaction between classification and reject performance for distance-based reject-option classifiers. Pattern Recognit Lett 27:908-917.
41. Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, Mooney SD, Radivojac P. 2009. Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25:2744-2750.
42. Liaw A, Wienner M. 2002. Classification and regression by randomForest. R News 2:18-22.
43. Masica DL, Karchin R. 2011. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res 71:4550-4561.
44. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER. 2011. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30:1390-1401.
45. Morse HG, Moore GE. 1993. Cytogenetic homogeneity in eight independent sites in a case of malignant melanoma. Cancer Genet Cytogenet 69:108-112.
46. Ng PC, Henikoff S. 2001. Predicting deleterious amino acid substitutions. Genome Res 11:863-874.
47. Nishikawa K, Ishino S, Takenaka H, Norioka N, Hirai T, Yao T, Seto Y. 1994. Constructing a protein mutant database. Protein Eng 7:733.
48. Piirilä H, Valiäho J, Vihinen M. 2006. Immunodeficiency mutation databases (IDbases). Hum Mutat 27:1200-1208.
49. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, et al. 2010. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-196.
50. Sexton J, Laake P. 2009. Standard errors for bagged and random forest estimators. Comput Stat Data Anal 53:801.
51. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308-311.
52. Sing T, Sander O, Beerenwinkel N, Lengauer T. 2005. ROCR: visualizing classifier performance in R. Bioinformatics 21:3940-3941.
53. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
54. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. 2009. The human gene mutation database: 2008 update. Genome Med 1:13.
55. Stone EA, Sidow A. 2005. Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. Genome Res 15:978-986.
56. Sun X, Essalmani R, Seidah NG, Prat A. 2009. The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Mol Cancer 8:73.
57. Thusberg J, Olatubosun A, Vihinen M. 2011. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 32:358-368.
58. Thusberg J, Vihinen M. 2009. Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat 30:703-714.
59. UniProt Consortium. 2011. Ongoing and future developments at the universal protein resource. Nucleic Acids Res 39:D214-D219.
60. Vihinen M. How to evaluate performance of prediction methods? Measures and their interpretation in variation effect analysis. BMC Genomics (in press).
61. Wei X, Moncada-Pazos A, Cal S, Soria-Valles C, Gartner J, Rudloff U, Lin JC, NISC Comparative Sequencing Program, Rosenberg SA, Lopez-Otin C, Samuels Y. 2011. Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. Hum Mutat 32:E2148-75.
62. Wei Q, Wang L, Wang Q, Kruger WD, Dunbrack RL Jr. 2010. Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase. Proteins 78:2058-2074.
63. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. 2008. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3:e2734.
64. Wolpert DH. 1992. Stacked generalization. Neural Networks 5:241-259.
65. Wu YY, Peck K, Chang YL, Pan SH, Cheng YF, Lin JC, Yang RB, Hong TM, Yang PC. 2011. SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene 30:3682-3693.
66. Yip YL, Scheib H, Diemand AV, Gattiker A, Famiglietti LM, Gasteiger E, Bairoch A. 2004. The swiss-prot variant page and the ModSNP database: a resource for sequence and structure information on human protein variants. Hum Mutat 23:464-470.